Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA121-28 in Advanced Biliary Tract Cancer
NCT04784520Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ha121-28 in biliary tract cancer (BTC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2021; status: terminated.
02
Drugs
ha121-28
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04784520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784520.